Hitting cancer early: AstraZeneca's bid to outmaneuver rivals

July 6, 2018 6:07 AM

48 0

LONDON (Reuters) - AstraZeneca (AZN.L) suffered its biggest daily share price drop a year ago after a key cancer drug trial failed amid feverish speculation the chief executive might quit.

Yet today two-thirds of analysts tracked by Thomson Reuters recommend the stock, making it one of the sector’s biggest consensus buys, and CEO Pascal Soriot says he is “absolutely” happy to carry on into the 2020s as he chases early use of modern cancer drugs.

Also read: Opioid maker Insys paid physician assistant kickbacks, U.S. jury hears

Read more

To category page

Loading...